We checked serum IL-17A levels in 122 breast cancer patients and found that IL-17A levels correlated with ER/PR-negative status, but not with HER2 expression and clinical tumor stage (p < 0.05, Figure 1A–1C). This evidence concerns the gene ERBB2 and breast cancer.